Integra Therapeutics is a biotechnology company focused on developing innovative gene writing tools to enhance the safety, precision, and efficacy of advanced therapies. Their lead technology, FiCAT, combines CRISPR precision with the efficiency of viral integrases and transposases to enable programmable delivery of large DNA sequences, aiming to overcome key limitations in gene therapy for genetic, oncological, and autoimmune diseases.
